Cornerstone Planning Group’s Arbutus Biopharma ABUS Stock Holding History

Cornerstone Planning Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4K	Hold	924	–	–	﹤0.01%	1143
2026 Q1	$4.07K	Hold	924	–	–	﹤0.01%	1140
2025 Q4	$3.83K	Hold	924	–	–	﹤0.01%	1046
2025 Q3	$4.47K	Hold	924	–	–	﹤0.01%	981
2025 Q2	$3.15K	Buy	924 +142	+18%	+$472	﹤0.01%	838
2025 Q1	$2.53K	Hold	782	–	–	﹤0.01%	923
2024 Q4	$2.68K	Hold	782	–	–	﹤0.01%	714
2024 Q3	$3.16K	Hold	782	–	–	﹤0.01%	669
2024 Q2	$2.83K	Hold	782	–	–	﹤0.01%	696
2024 Q1	$2.12K	Buy	+782	New	+$2.02K	﹤0.01%	658

Other funds holding ABUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

FCH

Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

LWA

Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return

Cornerstone Planning Group's ABUS Position: Q2 2026 in Review

Cornerstone Planning Group held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 924 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1143.

Cornerstone Planning Group first reported a position in ABUS in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.47K in Q3 2025. 65 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Cornerstone Planning Group held 924 shares of Arbutus Biopharma worth $4K as of Q2 2026.
Cornerstone Planning Group left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1143 holding.
Cornerstone Planning Group first reported a position in Arbutus Biopharma in Q1 2024 and has held it in 10 quarters since.
Cornerstone Planning Group's Arbutus Biopharma position peaked at $4.47K in Q3 2025.
65 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.